论文部分内容阅读
目的:探讨恶性脑胶质瘤手术后应用单药替莫唑胺(TMZ)方案化疗与尼莫司汀联合顺铂(ACNU+DDP)化疗的效果。方法:选取经病理证实为恶性脑胶质瘤患者60例,手术治疗后随机分为TMZ和ACNU+DDP两组,按标准方案分别给予4～6个疗程的化疗。每个化疗期间分别复查头颅MRI及肝肾功、血细胞分析,并与化疗前资料相比较,判断病情变化。结果:TMZ组有效率达为44.0%,ACNU+DDP组为14.28%,两组相差显著(P<0.05)。TMZ组严重副反应发生率为16.0%,ACNU+DDP组为31.43%,两组相差显著(P<0.05)。结论:TMZ比ACNU+DDP不仅能更好的改善恶性胶质瘤患者的预后,提高其生活质量,而且具有较高的安全性。
Objective: To investigate the effect of chemotherapy with temozolomide (TMZ) and nimustine combined with cisplatin (ACNU + DDP) after malignant glioma surgery. Methods: Sixty patients with malignant gliomas confirmed by pathology were selected and randomly divided into TMZ and ACNU + DDP groups. Four to six cycles of chemotherapy were given according to the standard protocol. During each chemotherapy were reviewed head MRI and liver and kidney function, blood cell analysis, and compared with pre-chemotherapy data to determine the condition changes. Results: The effective rate was 44.0% in TMZ group and 14.28% in ACNU + DDP group, the difference was significant (P <0.05). The incidence of serious side effects was 16.0% in TMZ group and 31.43% in ACNU + DDP group, with significant difference between the two groups (P <0.05). Conclusion: Compared with ACNU + DDP, TMZ can not only improve the prognosis and improve the quality of life of patients with malignant gliomas, but also have higher safety.